Conclusions
Initiation of ETI therapy is associated with reduced utilization of several CF medication, but changes in utilization did not have a clear impact on lung function within this study. In the real world, many PwCF on ETI may prioritize reducing treatment burden over maximizing lung function. Further study is needed to determine the clinical consequences of reduced adherence.
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
1. McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol . 2022;57(S1):S5-S12. doi:10.1002/ppul.25733
2. Moore BM, Laguna TA, Liu M, McNamara JJ. Increased adherence to CFF practice guidelines for pulmonary medications correlates with improved FEV1. Pediatr Pulmonol . 2013;48(8):747-753. doi:10.1002/ppul.22665
3. Mayer-Hamblett N, Ratjen F, Russell R, et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.Lancet Respir Med . 2023;11(April):2-4. doi:10.1016/S2213-2600(22)00434-9
4. Song JT, Desai S, Franciosi AN, Dagenais RVE, Quon BS. Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis. J Cyst Fibros . 2022;21(6):1080-1081. doi:10.1016/j.jcf.2022.05.005
5. Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am J Respir Crit Care Med . 2013;187(7):680-689. doi:10.1164/rccm.201207-1160OE
6. Nichols DP, Paynter AC, Heltshe SL, et al. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis A Clinical Trial. Am J Respir Crit Care Med . 2022;205(5):529-539. doi:10.1164/rccm.202108-1986OC